2023-04-25 13:17:27
The randomized, controlled, clinical FETRALS study examines the effectiveness of stool transplantation in patients with early amyotrophic lateral sclerosis (ALS). Data on the primary endpoint are not yet available, but initial analyzes do indeed show significant and defined abnormalities in the intestinal microbiome of ALS patients.
Oleksandra Troian/GettyImages
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults and is characterized by increasing muscle atrophy and functional impairment of voluntary motor functions. Incidence is 2.8 per 100,000 in Europe and 1.8 per 100,000 in North America. In most sufferers, ALS leads to death from respiratory failure within a few years. A hereditary genesis can be proven in five to ten percent of those suffering from ALS. The etiology of the more than 90 percent of the diseases that are sporadic has not yet been fully elucidated. According to Dr. Alessandra Guarnaccia from the Columbus-Gemelli University Hospital IRCCS in Rome. Both in the blood and in the cerebrospinal fluid of ALS patients, an increase in CD4+ T cells (TH2) is offset by a decrease in regulatory T cells (Treg), resulting in the typical picture of an inflammatory status. Measures to promote the Treg population are therefore expected, at least in theory, to have beneficial effects on the clinical picture of ALS.
Guarnaccia also points to increasing evidence that the gut microbiome modulates the systemic immune response. A cross talk between specific populations of intestinal bacteria (Proteobacteria) and the immune system might be demonstrated, which activates proinflammatory pathways and is associated with a loss of Treg.
1682435366
#Abnormal #gut #microbiome #amyotrophic #lateral #sclerosis
